Product Description
Sodium ascorbate is an organic sodium salt resulting from the replacement of the proton from the 3-hydroxy group of ascorbic acid by a sodium ion. It has a role as a food antioxidant, a flour treatment agent, a coenzyme, a plant metabolite, a human metabolite, a Daphnia magna metabolite and a reducing agent. It is an organic sodium salt and a vitamin C. It contains a L-ascorbate. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Sodium-ascorbate)
Mechanisms of Action: Iron Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous,Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Algeria | Australia | Austria | Belgium | Brazil | Chile | China | Colombia | Croatia | Cyprus | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Greece | Hong Kong | Hungary | India | Indonesia | Ireland | Malaysia | Malta | Mexico | Morocco | Norway | Pakistan | Philippines | Poland | Russia | Serbia | South Africa | Spain | Sweden | Taiwan | Ukraine | United Arab Emirates | United Kingdom | United States | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Norgine
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Acinar Cell Carcinoma|Adenocarcinoma|Breast Cancer|Ductal Breast Carcinoma|Pancreatic Cancer|Pancreatic Ductal Carcinoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| SHARON | P1 |
Recruiting |
Acinar Cell Carcinoma|Ductal Breast Carcinoma|Adenocarcinoma|Pancreatic Cancer|Pancreatic Ductal Carcinoma|Breast Cancer |
2025-12-01 |